Painful Sex After Menopause: Understanding GSM and Your Options
Dr. Karla Loken is a board-certified OB/GYN with over two decades of clinical experience and a distinguished career driving innovation in women's health across the pharmaceutical, diagnostics, and medical device industries. Through her consultancy, Loken & Associates, Dr. Loken provides medical affairs expertise and fractional Chief Medical Officer (CMO) services, helping early-stage companies bridge the gap between scientific innovation and industry application. She serves as Chief Medical Officer to MenoHealth. · 12 min read · Sep 2026
Medically reviewed by Karla F. Loken, DO, FACOOG on September 20, 2026
Painful sex after menopause has a name — GSM — and effective treatments. Vaginal estrogen, DHEA, lubricants, and how to talk to your doctor.
When hormones are robust, your genitals thrive — they're thick, they lubricate, they're healthy, they're acidic, and the microbiome is on point. When hormone levels start to drop, you start getting urinary frequency or urgency, itching, burning, and dryness — and you may start to have pain with sex. And the craziest thing is that Genitourinary Syndrome of Menopause was only coined in 2014.
If sex has become painful in a way it never was before, and you’ve been quietly tolerating it or quietly avoiding it, you’re in one of the most common — and most treatable — patterns of postmenopause. Painful sex after menopause has a specific underlying cause called genitourinary syndrome of menopause (GSM), and it doesn’t go away on its own. It also responds well to treatments most clinicians don’t bring up until you do.
This guide explains what GSM is, why painful sex is one of its core features, what your evidence-based options actually are, and how to have the clinical conversation that gets you to a real plan.
Key takeaways
Painful sex after menopause is almost always driven by genitourinary syndrome of menopause (GSM), a clinical entity defined by the Menopause Society in 2020.
GSM affects roughly half of postmenopausal women, often worsens with time, and rarely resolves without treatment.
Low-dose vaginal estrogen is the most effective treatment and is supported by strong evidence — including safety data in long-term use.
Non-hormonal options including vaginal moisturizers, vaginal DHEA (prasterone), ospemifene, and lubricants all have established roles.
The conversation with a clinician matters: most women never get to treatment because they never bring it up, and many clinicians never ask.
The short answer: what’s causing the pain
In the vast majority of cases, painful sex after menopause is caused by genitourinary syndrome of menopause (GSM) — a constellation of changes that follow sustained estrogen deficiency in the vagina, vulva, urethra, and bladder. The term, formalized in the Menopause Society’s 2020 GSM Position Statement, replaced the older “vaginal atrophy” because the changes affect more than just the vagina.
The vaginal and vulvar tissues are dense with estrogen receptors. When estrogen falls and stays low after menopause, those tissues become thinner, drier, less elastic, and more fragile. Blood flow decreases. Natural lubrication during arousal slows or stops. The vaginal pH rises, the microbiome shifts, and the result is tissue that’s easily irritated, easily torn, and easily painful with penetration.
Unlike hot flushes, GSM doesn’t ease with time. It typically worsens. That’s worth knowing because women are often advised to wait it out, and the underlying biology won’t reward waiting.
What GSM actually looks like
GSM is more than dyspareunia (painful sex). The Menopause Society 2020 statement defines it as a syndrome with vaginal, vulvar, and urinary components. You don’t need all of them to have GSM, but the more you have, the clearer the picture.
Vaginal symptoms: - Dryness, even at rest - Burning, itching, or irritation - Decreased lubrication during arousal - Pain with penetration (dyspareunia) - Light bleeding or spotting after intercourse - Discharge changes
Vulvar symptoms: - Thinning of the labia - Sensitivity to clothing, soaps, or wiping - Recurrent irritation
Urinary symptoms: - Urinary urgency - Frequency - Recurrent UTIs - Burning with urination without infection - Mild stress incontinence
About half of postmenopausal women have GSM symptoms, and the prevalence rises further into late postmenopause. Despite that, surveys consistently find that fewer than half of affected women raise it with a clinician, and fewer than 10% are receiving evidence-based treatment for it.
Why this matters more than the symptom itself
Vaginal hormones should be like giving out blood pressure medication to your patients — evidence-based, effective, and offered proactively. Women over 45 should be offered these therapies and understand how safe and effective they are.
Painful sex is often described as a “quality of life” issue, which understates the problem in ways that matter. Untreated GSM:
Erodes intimate relationships, often quietly, over years
Contributes to the cycle of recurrent UTIs that drives antibiotic use and sometimes hospitalization in older women
Worsens urinary incontinence and the social isolation that can come with it
Causes pelvic floor changes — guarding, hypertonicity — that compound the original tissue problem and create their own pain
The Menopause Society’s 2020 statement is explicit: GSM is undertreated, is associated with significant impact on intimacy and well-being, and has effective treatments. The framing isn’t “you have to put up with this.” It’s “this is a treatable medical condition, and there’s no clinical reason to leave it untreated.”
What actually works
The evidence base for GSM treatment is robust, and the options are broader than most women are told.
Vaginal estrogen (first-line)
Low-dose vaginal estrogen — available as creams, tablets, inserts, and rings — is the most effective treatment for moderate-to-severe GSM and is endorsed by the Menopause Society’s 2020 GSM Position Statement, the Menopause Society’s 2022 Hormone Therapy Position Statement, and NICE Guideline NG23 as first-line treatment.
Mechanism: it restores the local estrogen environment of the vagina, vulva, and lower urinary tract. Tissue thickens, elasticity returns, the microbiome normalizes, and lubrication during arousal improves over weeks to months.
Safety: at the doses used for GSM, systemic absorption is minimal. The largest safety analysis comes from Crandall and colleagues’ analysis of the Women’s Health Initiative Observational Study, published in Menopause in 2018, which found no increased risk of cardiovascular disease, cancer, or hip fracture in vaginal estrogen users over a median 7.2 years of follow-up. This is fundamentally different from systemic hormone therapy in both dose and risk profile.
Practical notes: most women start with a loading phase (daily for two weeks) then move to maintenance (typically twice a week). Effect builds over 6-12 weeks. Symptom recurrence is the rule if treatment is stopped — this is generally a long-term therapy. Our is vaginal estrogen safe guide covers the safety question in detail, including for women with a history of breast cancer.
Vaginal moisturizers and lubricants
Doctors are not trained to give a crap about your sexual health, and that's a problem. Your sexual health is health. It is your wellbeing. It is joy, it is pleasure, and it is really, really important.
Non-hormonal vaginal moisturizers (used regularly, typically two to three times per week) and lubricants (used at the time of sex) are the foundation of non-hormonal management. They work, particularly for mild GSM, and they’re a reasonable starting point or adjunct.
Moisturizers and lubricants are different products: moisturizers are designed for routine use and longer-acting hydration of vaginal tissue; lubricants are designed to reduce friction at the time of activity. Water-based lubricants are condom-compatible and widely available; silicone-based lubricants last longer and are particularly useful for GSM, though they shouldn’t be used with silicone toys.
Avoid products with glycerin, parabens, propylene glycol, or fragrance if your tissue is reactive — postmenopausal vaginal tissue is more sensitive to irritants.
Vaginal DHEA (prasterone)
Vaginal DHEA, sold as prasterone, is an FDA-approved daily vaginal insert that works through local conversion of DHEA to estrogen and testosterone in vaginal tissue. It has evidence comparable to vaginal estrogen for dyspareunia and is an option for women who can’t or don’t want to use vaginal estrogen directly.
Ospemifene
Ospemifene is an oral selective estrogen receptor modulator (SERM) approved for moderate-to-severe dyspareunia due to menopause. It acts like estrogen on vaginal tissue and is non-estrogen at other sites. It’s an option particularly for women who prefer oral therapy or who can’t use vaginal products. It has its own contraindications and side effect profile that a clinician should walk through.
Pelvic floor physical therapy
If GSM has been untreated long enough, secondary pelvic floor dysfunction often develops — the muscles tighten in anticipation of pain, which adds its own layer of dyspareunia that won’t resolve with hormones alone. Pelvic floor physical therapy is highly effective for this component and is often combined with vaginal estrogen rather than chosen instead of it.
Things that aren’t first-line
Systemic hormone therapy — pills, patches, gels — is not the first choice for isolated GSM. If you have moderate-to-severe vasomotor symptoms and GSM, systemic HRT may address both. If GSM is your only issue, vaginal estrogen at a fraction of the systemic dose is more targeted.
Energy-based devices (vaginal CO2 lasers, radiofrequency) have been heavily marketed and are not endorsed as first-line by either the Menopause Society or major regulators. The evidence is mixed, the cost is high, and the FDA has issued a safety communication on the marketing of these devices for menopause symptoms.
Most “vaginal rejuvenation” supplements and oils don’t have published efficacy data and aren’t appropriate substitutes for the evidence-based options above.
The conversation that gets you to treatment
Most women with GSM never get treated because they never bring it up. Many clinicians never ask. Closing that gap is the highest-yield single step you can take.
A practical script:
“Sex has become painful since menopause. I think this might be GSM. I’d like to talk about whether vaginal estrogen, vaginal DHEA, or another option would be appropriate for me.”
That sentence does three things: it names the problem, it names the diagnosis, and it names the treatment categories. Most clinicians will engage substantively with that prompt even if they wouldn’t have raised the topic themselves.
If you have a personal history of breast cancer, raise it explicitly — both vaginal estrogen and vaginal DHEA are used in selected breast cancer survivors after a discussion with the oncology team, and the vaginal estrogen safety guide covers what the current evidence shows. The tamoxifen side effects guide covers the parallel scenario of GSM during anti-estrogen treatment.
If your clinician dismisses the conversation, that’s a reason to find a clinician who’s current with the evidence — not a reason to stop seeking treatment. A clinician comfortable with menopause care will recognize GSM, walk through the options, and prescribe.
When to talk to a clinician
Painful sex after menopause is reason enough on its own. Other triggers include:
Vaginal dryness, burning, or itching that’s persistent
Recurrent UTIs or burning with urination
New urinary urgency or frequency
Spotting or light bleeding after intercourse (always evaluate; can be GSM, can be something else)
Symptoms in the setting of breast cancer survivorship or tamoxifen use
Any bleeding in postmenopause not associated with intercourse (this needs evaluation regardless of cause)
For a broader framework on raising these conversations, the talking to your doctor about menopause guide walks through how to prepare.
Frequently asked questions
Will painful sex after menopause get better on its own?
Usually not. Unlike hot flushes, GSM typically worsens over time without treatment. Most cases respond well to vaginal estrogen, vaginal DHEA, or other targeted options.
Is vaginal estrogen safe long-term?
The largest safety analysis (Crandall 2018, Menopause) found no increased risk of cardiovascular disease, cancer, or hip fracture over a median 7.2 years. Local vaginal estrogen has minimal systemic absorption and a fundamentally different risk profile from systemic HRT.
Can I use vaginal estrogen if I’ve had breast cancer?
This is an individualized decision made with your oncology team. Vaginal estrogen is increasingly used in breast cancer survivors with persistent GSM after non-hormonal options have been tried, and major societies including the Menopause Society have endorsed this approach in selected cases. Aromatase inhibitor users require particular caution and oncology input.
Are over-the-counter lubricants enough?
For mild GSM, sometimes — particularly when combined with a vaginal moisturizer used regularly. For moderate-to-severe symptoms, lubricants alone usually aren’t enough, because they don’t address the underlying tissue change.
Will my partner know I’m using vaginal estrogen?
Most vaginal estrogen products are absorbed locally and don’t transfer significantly. Cream formulations can transfer if applied immediately before sex; waiting a few hours after application or using a tablet or ring avoids this concern.
How long until vaginal estrogen works?
Most women notice improvement within 4-6 weeks, with continued improvement over 12 weeks. Full benefit typically takes 3 months of consistent use.
Sources
The Menopause Society. The 2020 Genitourinary Syndrome of Menopause Position Statement of The North American Menopause Society. Menopause. 2020;27(9):976-992.
The Menopause Society. The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause. 2022;29(7):767-794.
Crandall CJ, Hovey KM, Andrews CA, et al. Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women’s Health Initiative Observational Study. Menopause. 2018;25(1):11-20.
National Institute for Health and Care Excellence. Menopause: identification and management (NG23). Updated November 2024.
The Menopause Society. The 2023 Nonhormone Therapy Position Statement of The North American Menopause Society. Menopause. 2023;30(6):573-590.
Disclaimer
This article is for educational purposes and does not constitute medical advice. Always consult a qualified healthcare provider for guidance on your specific situation. Prescription products referenced (vaginal estrogen, vaginal DHEA/prasterone, ospemifene, systemic hormone therapy) require evaluation by a clinician and are not appropriate for everyone. Postmenopausal bleeding not associated with intercourse should be evaluated promptly regardless of suspected cause.
